scholarly journals Assessing Determinants of the Current Account Deficit: A case study of India

2021 ◽  
Vol 11 (1) ◽  
pp. 23-32
Author(s):  
Jamshed Haidery ◽  
Zabihullah Shokuri
Keyword(s):  
Breast Cancer ◽  
Current Account Deficit ◽  
Clinical Stage ◽  
Diagnostic Value ◽  
Established Tumor ◽  
Qualitative Detection ◽  
Potential Indicator ◽  
Circulating Levels ◽  
Higher Sensitivity

The Objective: one of the essential regulators of carcinogenesis is MicroRNA-21 (miR-21). Yet little light has been shed on its effectiveness as a tumor marker compared to the conventional ones. Comparing the diagnostic value of established tumor markers in breast cancer (BC) such as carcinoembryonic antigen (CEA) and CA153 with circulating level of miR-21 is the aim of this study.Methods:The study included 89 BC patients. Amplification of the circulating levels of miR-21 and miR-16 done using real-time PCR qualitative detection, while electrochemiluminescence assays was used to detect circulating levels of CEA and CA153. The diagnostic sensitivity for BC was compared between the three.Results: the serum miR-21 levels were high significantly BC patients, as the latter had much higher levels (P<0.001). the CA153 and CEA sensitivities were 15.73% and 22.47% respectively, while miR-21 Sensitivity and specificity were 87.6% and 87.3%.Conclusion:in BC patients miR-21 exhibits far higher sensitivity for diagnoses than both CEA and CA153. Thus especially in the early stages of BC, miR-21 can become a potential indicator for diagnosis, albeit the clinical stage, PR and ER statuses were not correlated in this study.

scholarly journals Clinical significance of serum mir-21,ca153 and cea in breast cancer

2021 ◽  
Vol 11 (1) ◽  
pp. 33-37
Author(s):  
Ali Rostam
Keyword(s):  
Breast Cancer ◽  
Tumor Marker ◽  
Real Time Pcr ◽  
Clinical Stage ◽  
Diagnostic Value ◽  
Established Tumor ◽  
Qualitative Detection ◽  
Potential Indicator ◽  
Circulating Levels ◽  
Higher Sensitivity

The Objective: one of the essential regulators of carcinogenesis is MicroRNA-21 (miR-21). Yet little light has been shed on its effectiveness as a tumor marker compared to the conventional ones. Comparing the diagnostic value of established tumor markers in breast cancer (BC) such as carcinoembryonic antigen (CEA) and CA153 with circulating level of miR-21 is the aim of this study.Methods:The study included 89 BC patients. Amplification of the circulating levels of miR-21 and miR-16 done using real-time PCR qualitative detection, while electrochemiluminescence assays was used to detect circulating levels of CEA and CA153. The diagnostic sensitivity for BC was compared between the three.Results: The serum miR-21 levels were high significantly BC patients, as the latter had much higher levels (P<0.001). the CA153 and CEA sensitivities were 15.73% and 22.47% respectively, while miR-21 Sensitivity and specificity were 87.6% and 87.3%.Conclusion:in BC patients miR-21 exhibits far higher sensitivity for diagnoses than both CEA and CA153. Thus especially in the early stages of BC, miR-21 can become a potential indicator for diagnosis, albeit the clinical stage, PR and ER statuses were not correlated in this study.

scholarly journals MicroRNA-411 represents an innovative bio-marker in breast cancer detection

2020 ◽  
Author(s):  
Shuangqing Cao ◽  
Lei Zheng
Keyword(s):  
Breast Cancer ◽  
Serum Level ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Histological Grade ◽  
Clinical Stage ◽  
Breast Cancer Diagnosis ◽  
Diagnostic Value ◽  
Healthy Controls ◽  
Breast Cancer Patients

Abstract Background: MicroRNA-411 (MiR-411) has been reported to play an important role in tumorigenesis. This study was aimed to investigate the diagnostic performance of serum miR-411 in breast cancer.Methods: The serum level of miR-411 was determined in breast cancer patients using quantitative real-time PCR (qRT-PCR). Chi-square was applied to evaluate the association between miR-411 expression and clinical characteristics. The diagnostic value of serum miR-411 for breast cancer was estimated using receiver operator characteristic (ROC) analysis.Results: Serum miR-411 in patients with breast cancer was markedly decreased compared with healthy controls (P < 0.001). The level of miR-411 was correlated with clinical stage (P = 0.019), histological grade (P = 0.014), and lymph node metastasis (P = 0.036). ROC curve showed that serum level of miR-411 could discriminate between breast cancer patients and healthy controls, with the AUC of 0.796, combing with the sensitivity of 82.1% and the specificity of 83.2%. The cut-off value of miR-411 for breast cancer diagnosis was 1.245.Conclusions: MiR-411 plays inhibitory roles in aggressive progression of breast cancer. Serum miR-411 may be a potential non-invasive biomarker for breast cancer diagnosis.

scholarly journals DNAJC3-AS1 Is Associated with Proliferation, Metastasis, and Poor Prognosis of Breast Cancer

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Yi Zhang ◽  
Jing-jing Li ◽  
Bo Luo ◽  
Xiao-fei Guo ◽  
Jian-xin Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Noncoding Rna ◽  
Clinical Stage ◽  
Disease Free Survival ◽  
Diagnostic Value ◽  
Normal Breast ◽  
Free Survival ◽  
Diagnostic Assays ◽  
Related Proteins ◽  
Disease Free

Objective. Long noncoding RNA DNAJC3-AS1 (DNAJC3-AS1) was a newly identified tumor-related lncRNA. The aim of the present study was to explore the prognostic value and diagnostic of DNAJC3-AS1 (DNAJC3-AS1) expression in breast cancer (BC) patients. Patients and Methods. The expression of DNAJC3-AS1 was detected in 170 BC tissues and matched normal breast samples by qRT-PCR. The diagnostic value of DNAJC3-AS1 was examined by receiver-operating characteristic (ROC) assays. The correlation of DNAJC3-AS1 with clinicopathological features and prognosis was also statistically analyzed. CCK-8 assays, colony formation assays, and Transwell assays were applied to examine the potential function of DNAJC3-AS1 on tumor progression. Western blot was used to examine the expression of EMT-related proteins. Results. The expression of DNAJC3-AS1 in BC specimens was higher than that in the adjacent nontumor tissues ( p < 0.01 ). Diagnostic assays revealed that DNAJC3-AS1 has considerable diagnostic accuracy, with an area under the ROC curve (AUC) of 0.7457 ( p < 0.001 ). High DNAJC3-AS1 expression was positively associated with lymph node metastasis ( p = 0.010 ) and clinical stage ( p = 0.023 ). A survival study revealed that patients with high DNAJC3-AS1 expression had shorter overall survival ( p = 0.0067 ) and disease-free survival ( p < 0.0001 ) than those with low DNAJC3-AS1 expression. More importantly, multivariate assays indicated that DNAJC3-AS1 was an independent prognostic factor in BC patients. Functional assays confirmed that silence of DNAJC3-AS1 distinctly suppressed the proliferation, metastasis, and EMT progress of BC cells. Conclusions. DNAJC3-AS1 may be a prognostic and diagnostic biomarker for BC patients.

Optimizing Breast Cancer Follow-up Care: Diagnostic Value and Costs of Additional Routine Breast Ultrasound

2010 ◽  
Vol 31 (S 01) ◽  
Author(s):  
S Wojcinski ◽  
A Farrokh ◽  
U Hille ◽  
E Hirschauer ◽  
W Schmidt ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Diagnostic Value ◽  
Breast Ultrasound ◽  
Follow Up Care

Value of cone beam computed tomography to evaluate complication of intracranial haemorrhage in endovascular treatment (evt): a case report

2019 ◽  
Vol 1 (1) ◽  
pp. 16-18 ◽  
Author(s):  
Norafida Bahari ◽  
Nik Azuan Nik Ismail ◽  
Jegan Thanabalan ◽  
Ahmad Sobri Muda
Keyword(s):  
Computed Tomography ◽  
Arteriovenous Malformation ◽  
Endovascular Treatment ◽  
Cone Beam Computed Tomography ◽  
Diagnostic Value ◽  
Cone Beam ◽  
Brain Arteriovenous Malformation ◽  
Embolic Materials

In this article, we evaluate the effectiveness of Cone Beam Computed Tomography, through a case study, in assessing the complication of intracranial bleeding during an endovascular treatment of brain arteriovenous malformation when compared to Multislice-Detector Computed Tomography performed immediately after the procedure. The image quality of Cone Beam Computed Tomography has enough diagnostic value in differentiating between haemorrhage, embolic materials and the arteriovenous malformation nidus to facilitate physicians to decide for further management of the patient.

Value of cone beam computed tomography to evaluate complication of intracranial haemorrhage in endovascular treatment (evt): a case report.

2019 ◽  
pp. 16-18
Author(s):  
Norafida Bahari ◽  
NikAzuan Nik Ismail ◽  
Jegan Thanabalan ◽  
Ahmad Sobri Muda
Keyword(s):  
Computed Tomography ◽  
Arteriovenous Malformation ◽  
Endovascular Treatment ◽  
Cone Beam Computed Tomography ◽  
Diagnostic Value ◽  
Cone Beam ◽  
Brain Arteriovenous Malformation ◽  
Embolic Materials

In this article, we evaluate the effectiveness of Cone Beam Computed Tomography, through a case study, in assessing the complication of intracranial bleeding during an endovascular treatment of brain arteriovenous malformation when compared to Multislice-Detector Computed Tomography performed immediately after the procedure. The image quality of Cone Beam Computed Tomography has enough diagnostic value in differentiating between haemorrhage, embolic materials and the arteriovenous malformation nidus to facilitate physicians to decide for further management of the patient.

Positron emission mammography in the diagnosis of breast cancer

2016 ◽  
Vol 55 (01) ◽  
pp. 15-20 ◽  
Author(s):  
J. Farahati ◽  
A. G. Müller ◽  
E. Gillman ◽  
M. Hentschel ◽  
F. H. H. Müller
Keyword(s):  
Breast Cancer ◽  
High Specificity ◽  
Diagnostic Value ◽  
Glandular Tissue ◽  
Breast Cancer Patients ◽  
Malignant Tumours ◽  
Benign Lesions ◽  
Interventional Study ◽  
Positron Emission Mammography ◽  
Positron Emission

SummaryAim: To evaluate the diagnostic value (sensitivity, specificity) of positron emission mammography (PEM) in a single site non-interventional study using the maximum PEM uptake value (PUVmax). Patients, methods: In a singlesite, non-interventional study, 108 patients (107 women, 1 man) with a total of 151 suspected lesions were scanned with a PEM Flex Solo II (Naviscan) at 90 min p.i. with 3.5 MBq 18F-FDG per kg of body weight. In this ROI(region of interest)-based analysis, maximum PEM uptake value (PUV) was determined in lesions, tumours (PUVmaxtumour), benign lesions (PUVmaxnormal breast) and also in healthy tissues on the contralateral side (PUVmaxcontralateral breast). These values were compared and contrasted. In addition, the ratios of PUVmaxtumour / PUVmaxcontralateral breast and PUVmaxnormal breast / PUVmaxcontralateral breast were compared. The image data were interpreted independently by two experienced nuclear medicine physicians and compared with histology in cases of suspected carcinoma. Results: Based on a criteria of PUV>1.9, 31 out of 151 lesions in the patient cohort were found to be malignant (21%). A mean PUVmaxtumour of 3.78 ± 2.47 was identified in malignant tumours, while a mean PUVmaxnormal breast of 1.17 ± 0.37 was reported in the glandular tissue of the healthy breast, with the difference being statistically significant (p < 0.001). Similarly, the mean ratio between tumour and healthy glandular tissue in breast cancer patients (3.15 ± 1.58) was found to be significantly higher than the ratio for benign lesions (1.17 ± 0.41, p < 0.001). Conclusion: PEM is capable of differentiating breast tumours from benign lesions with 100% sensitivity along with a high specificity of 96%, when a threshold of PUVmax >1.9 is applied.

Serum Carboxypeptidase N1 Serves as a Potential Biomarker Complementing CA15-3 for Breast Cancer

2020 ◽  
Vol 20 (17) ◽  
pp. 2053-2065
Author(s):  
Ranliang Cui ◽  
Chaomin Wang ◽  
Qi Zhao ◽  
Yichao Wang ◽  
Yueguo Li
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Critical Concentration ◽  
Tumour Size ◽  
Clinical Stage ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Potential Biomarker ◽  
Incidence And Mortality ◽  
Combined Detection

Background: The incidence and mortality of breast cancer are increasing annually. Breast cancer seriously threatens women's health and quality of life. We aimed to measure the clinical value of CPN1, a new serum marker of breast cancer and to evaluate the efficacy of CPN1 in combination with CA15-3. Methods: Seventy samples of breast cancer with lymph node metastasis, seventy-three samples of nonmetastatic breast cancer and twenty-five samples of healthy human serum were collected. Serum CA15-3 concentration was determined by Roche Elecsys, and serum CPN1 concentration was determined by ELISA. Results: In breast cancer patients, serum CPN1 concentration was positively correlated with tumour size, clinical stage and CA15-3 concentration (r = 0.376, P<0.0001). ROC curve analysis showed that the optimal critical concentration of CPN1 for breast cancer diagnosis was 32.8pg/ml. The optimal critical concentration of CPN1 in the diagnosis of metastatic breast cancer was 66.121pg/ml. CPN1 has a greater diagnostic ability for breast cancer (AUCCA15-3=0.702 vs. AUCCPN1=0.886, P<0.0001) and metastatic breast cancer (AUCCA15-3=0.629 vs. AUCCPN1=0.887, P<0.0001) than CA15-3, and the combined detection of CA15-3 and CPN1 can improve the diagnostic efficiency for breast cancer (AUCCA15-3+CPN1=0.916) and for distinguishing between metastatic and non-metastatic breast cancer (AUCCA15-3+CPN1=0.895). Conclusion: CPN1 can be used as a new tumour marker to diagnose and evaluate the invasion and metastasis of breast cancer. The combined detection of CPN1 and CA15-3 is more accurate and has a certain value in clinical application.

scholarly journals Discovery and function exploration of microRNA-155 as a molecular biomarker for early detection of breast cancer

Breast Cancer ◽  
2021 ◽  
Author(s):  
Xuemin Liu ◽  
Qingyu Chang ◽  
Haiqiang Wang ◽  
Hairong Qian ◽  
Yikun Jiang
Keyword(s):  
Breast Cancer ◽  
Early Detection ◽  
Protein Interactions ◽  
Meta Analysis ◽  
Enrichment Analysis ◽  
Diagnostic Value ◽  
Diagnostic Biomarker ◽  
Analysis Model ◽  
Sensitivity Specificity ◽  
Function Enrichment

Abstract Background MicroRNA-155 (miR-155) may function as a diagnostic biomarker of breast cancer (BC). Nevertheless, the available evidence is controversial. Therefore, we performed this study to summarize the global predicting role of miR-155 for early detection of BC and preliminarily explore the functional roles of miR-155 in BC. Methods We first collected published studies and applied the bivariate meta-analysis model to generate the pooled diagnostic parameters of miR-155 in diagnosing BC such as sensitivity, specificity and area under curve (AUC). Then, we applied function enrichment and protein–protein interactions (PPI) analyses to explore the potential mechanisms of miR-155. Results A total of 21 studies were finally included. The results indicated that miR-155 allowed for the discrimination between BC patients and healthy controls with a sensitivity of 0.87 (95% CI 0.78–0.93), specificity of 0.82 (0.72–0.89), and AUC of 0.91 (0.88–0.93). In addition, the overall sensitivity, specificity and AUC for circulating miR-155 were 0.88 (0.76–0.95), 0.83 (0.72–0.90), and 0.92 (0.89–0.94), respectively. Function enrichment analysis revealed several vital ontologies terms and pathways associated with BC occurrence and development. Furthermore, in the PPI network, ten hub genes and two significant modules were identified to be involved in some important pathways associated with the pathogenesis of BC. Conclusions We demonstrated that miR-155 has great potential to facilitate accurate BC detection and may serve as a promising diagnostic biomarker for BC. However, well-designed cohort studies and biological experiments should be implemented to confirm the diagnostic value of miR-155 before it can be applied to routine clinical procedures.

Sign in / Sign up

Export Citation Format

Share Document